L

Lineage Cell Therapeutics Inc
F:BT3

Watchlist Manager
Lineage Cell Therapeutics Inc
F:BT3
Watchlist
Price: 1.37 EUR -0.72%
Market Cap: 258.6m EUR

Gross Margin
Lineage Cell Therapeutics Inc

97.6%
Current
94%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.6%
=
Gross Profit
10.6m
/
Revenue
10.9m

Gross Margin Across Competitors

No Stocks Found

Lineage Cell Therapeutics Inc
Glance View

Market Cap
258.6m EUR
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

BT3 Intrinsic Value
1.42 EUR
Undervaluation 4%
Intrinsic Value
Price
L
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.6%
=
Gross Profit
10.6m
/
Revenue
10.9m
What is the Gross Margin of Lineage Cell Therapeutics Inc?

Based on Lineage Cell Therapeutics Inc's most recent financial statements, the company has Gross Margin of 97.6%.

Back to Top